Introduction
Chronic myeloid leukemia (CML) is a clonal disorder of the pluripotent hemopoietic stem cell, in which a reciprocal translocation t(9;22)(q34;q11) forms a Philadelphia (Ph) chromosome and creates a novel fusion gene, bcr-abl. Its corresponding protein has a constitutively activated tyrosine kinase that is central to the pathogenesis of CML.
Imatinib mesylate is a selective BCR-ABL protein tyrosine kinase inhibitor against ABL oncoproteins (c-ABL, BCR-ABL, ETV1-ABL), c-KIT and platelet-derived growth factor receptor. 1 In newly diagnosed patients, imatinib gives a complete hematological response in 95% of patients, and a complete cytogenetic response (CgR) in 76%. Although 57% of the patients have a 3-log reduction in the bcr-abl/bcr ratio compared to a predefined standard, only 4% show a complete molecular response. 2 Despite the high rate of response to imatinib therapy, the emergence of resistance to this treatment has been recognized as a major problem in the therapy of Phpositive CML patients. 3, 4 Some important imatinib resistance mechanisms have been characterized, including mutations in the BCR-ABL domain and overexpression of BCR-ABL oncoprotein, [5] [6] [7] [8] although these two mechanisms are associated with secondary or acquired resistance. Intrinsic resistance to imatinib has been linked to rapid drug efflux from hematopoietic cells and inactivation of imatinib by binding to serum a1-acid glycoprotein, 9 although supporting in vivo data are lacking. Other resistance mechanisms have been demonstrated, such as src-kinase LYN overexpression, 10 or proposed, like constitutive nuclear factor (NF)-kB activation. 11, 12 Taking into account the diversity of the mechanisms involved in imatinib resistance, we employed expression profiling to identify genes that may be involved in this resistance, as determined by cytogenetic and molecular responses. These results also provide insight into the mechanisms leading to this resistance.
Materials and methods

Patients
Patients were evaluated for cytogenetic and hematological responses for a minimum of 12 months. Bone marrow samples were collected before imatinib treatment (baseline), and after 3, 6, 9 and 12 months for cytogenetic studies. Thirty-two CML patients included in this study belong to a series of CML patients treated with imatinib after interferon (IFN)-a failure. The set of patients for validation comprised 12 people who had been treated with imatinib as first-line therapy. All patients were treated with identical doses of imatinib mesylate (400 mg daily) (STI571, Gleevec; Novartis Pharmaceuticals, East Hanover, NJ, USA). Informed consent was obtained from all patients enrolled in the study under the supervision of the local ethical committees.
Samples
Total RNA was extracted from bone marrow samples of 44 patients diagnosed with CML and from three bone marrow samples of healthy donors (see Supplementary Materials and methods for details).
complete (Ph þ 0%) and partial (Ph þ 1-34%) CgR; and nonresponders: minimal (Ph þ 35-99%) or no (Ph þ 100%) response. Deletions on the 5 0 region of the abl breakpoint were considered in the absence of one fusion pattern.
Expression profile analysis
Total RNA extraction, T-7-based RNA amplification, complementary DNA (cDNA)-probe preparation and hybridization were carried out as described previously. 13, 14 Microarray studies were performed using the CNIO OncoChip cDNA microarray, which contains 6386 genes represented by 7237 clones, including cancer-relevant genes. Scanning and analysis were carried out using the Agilent G2565AA Microarray Scanner System (Agilent Technologies, Inc., Rib Alto, CA, USA).
Raw microarray data were normalized using a global loss normalization (DNMAD program; http://dnmad.bioinfo.cnio.es/). The Cy3:Cy5 ratios of the duplicated spots of the array were averaged. The tumoral bone marrow samples were referenced against normal bone marrow data, thus providing a differential expression signature for each gene in the CML samples compared to normal bone marrow.
To analyze genes potentially involved in imatinib resistance, eight gene-functional categories were selected for the analysis: NF-kB pathway (144 genes); adhesion (121 genes); drug resistance, metabolism and membrane transport (116 genes); DNA repair (45 genes), kinases and phosphatases (25 genes); cytokines/immune response (51 genes), apoptosis (118 genes) and proliferation (194 genes) (Supplementary Table 1 ).
All microarray normalized data and microarray methodology details are included in the supplementary information (Supplementary Table 2 and Supplementary Materials and methods). The array experiments are available in the Array Express database (http://www.ebi.ac.uk/miamexpress/login.html) accession number: E-MEXP-388 The SOTA (Self-Organizing Tree Algoritham). clustering program (http://bioinfo.cnio.es/cgi-bin/ tools/clustering/sotarray) was used for cluster analysis, and trees were viewed using the TreeView program.
Statistical analysis -cytogenetic response
Expression profile data of responders and non-responders were compared using the Wilcoxon test. Odds ratios (ORs) from unconditional logistic regression models were computed to assess the association of each gene with the absence of response. Predicted values served to evaluate the percentage of patients correctly classified by the corresponding model. A gene was considered to be possibly associated with lack of CgR to treatment if the following three conditions were fulfilled: (1) the difference between the median value in responders and nonresponders was at least 0.20 (log-ratio value); (2) at least 75% of patients were correctly classified by the model (although this is a crude analysis, as it does not correct the optimism generated by using the same sample for testing and prediction); and (3) its OR had a probability of o0.10. For these selected genes, the process was repeated using bootstrapping methods (10 000 replications) to obtain more accurate confidence intervals, as well as to obtain a more realistic predictive value for that particular gene, correcting the over-optimistic estimates derived from the use of a single-sample 15 (see Supplementary Materials and methods). All the data from the univariate analysis for detecting genes associated with CgR to imatinib are included in the supplementary information (Supplementary Table 3) .
Prediction model
Multivariate model for later CgR (12 months). A gene was included in the multivariate model if the following three conditions were fulfilled: (1) the difference between the median value of responders and non-responders was at least 0.20 (logratio value); (2) at least 65% of patients were correctly classified (using the corrected estimation of accuracy, calculated by bootstrapping); and (3) its OR had a probability of o0. 10 .
Given the small number of patients available for this study, a factorial analysis was performed, which considered those genes associated with the response according to the aforementioned criteria. This involved the first three factors, which explained around 90% of the total variance. Each factor is constructed from a linear combination of a smaller number of genes. Factors were introduced in a logistic model and the most significant of them was kept. The final model was that which could not be improved by the inclusion of any other factor or single gene. It was validated by bootstrapping, and its capacity to predict adequately the response in those patients rejected in the sampling process was also considered. Finally, this model was used to predict the response of an independent sample of 12 patients who subsequently became available. The model was applied to the expression data obtained by microarray hybridization with the validation set.
Mutational studies
Mutational analysis was performed by directly sequencing an 816-bp region of the ATP-binding region of BCR-ABL, as described previously. 7 The mutation was performed in 22 samples before imatinib treatment and 10 post-treatment samples. As a control, we used a post-treatment case with a mutation (ValMet) at position 244. This patient was not included in the study, owing to the absence of an imatinib pretreatment sample.
Real-time reverse transcriptase-polymerase chain reaction
Some of the most significant genes have been validated by quantitative (Q) reverse transcriptase-polymerase chain reaction (RT-PCR), which was performed using TaqMan Gene Expression Assays (http://myscience.appliedbiosystems.com (Applied Biosystems, Foster City, CA, USA): c-FLAR -Hs00236002_m1; IKBKBHs00826074_m1; TNC-Hs00233648_m1; VWF-Hs00169795_ m1; PTGS1-Hs00377721_m1; SOCS2 -Hs00374416_m1; IL7R -Hs00233682_m1; BIRC4-Hs00153439_m1. As a control gene, GUS (primer probe set supply by Applied Biosystems: assay on demand Hs99999908_m1) has been used to validate the genes detected in the array study (Applied Biosystems, Foster City, CA, USA). In all cases, a standard curve based on at least three concentrations (represented in duplicate or triplicate) of a control cDNA was constructed for both the endogenous GUS control gene and genes of interest. In all cases, standard curves had a correlation coefficient 40.99. Calculations were based on two or three replicates in each case.
Results
Clinical characteristics of patients
Patient ages ranged from 15 to 72 years, with a median of 46 years. All patients were in the chronic phase, and all of them were considered refractory to IFN-a treatment. The median proportion of Ph þ cells was 92% (44-100%). Six patients had additional chromosomal alterations at the time of diagnosis (three had a deletion in the 9q þ region) ( Table 1, Supplementary Table 4 ).
Assessment of cytogenetic response
Imatinib induced a complete hematological response in all of the 31 patients treated for at least 12 months: a major cytogenetic response (MCgR) in 20 (65%), and a complete CgR in 12 (38%). The proportion of imatinib-sensitive patients increased over time; thus, the number of patients showing MCgR increased from 56% (14/25) at 6 months to 65% (20/31) at 12 months. Concerning MCgR, the patients were classified as early responders (6 months), late responders (12 months) and nonresponders (Table 1) .
Other classical predictor variables were also included. Thus, the presence of additional chromosomal abnormalities, the lack of a complete hematological response and the proportion of Phpositive cells were significantly associated with the lack of MCgR at 6 months (P ¼ 0.005, 0.03 and 0.031, respectively). There was no such association when the analysis was repeated for CgR at 12 months (Supplementary Table 4 ). Other clinical variables, such as sex, age and time since diagnosis, were not correlated with the lack of CgR at either time (6 and 12 months) (Supplementary Table 4 ).
Mutations in the abl kinase domain
Although our main interest was to detect intrinsic imatinib resistance, a mutational analysis was performed by directly sequencing the 816-bp region of abl encoding for the ATPbinding site and the kinase activation loop, as described previously. 7 No mutations were detected in any of the 21 pretreatment and 10 post-treatment samples analyzed. On the basis of their cytogenetics, 15 of the samples were considered to be responders at 12 months and six were considered nonresponders. Eight of the 11 non-responder cases were analyzed at the time of resistance.
Identification of genes associated with imatinib resistance
The expression profile of these 32 cases, obtained with the cDNA microarray OncoChip, gives a set of 46 genes that were differentially expressed in responders and non-responders to imatinib (Table 2 and Figure 1 ) (array data in Supplementary Table 2 and bootstrap analysis in Supplementary Table 3) .
Repression of cell-adhesion molecules and activation of molecules involved in drug metabolism seem to be signaled by these findings as being a major contributor to imatinib resistance, although other cell functions are also implicated, such as activated tyrosine kinase activity and WNT signaling. Some of the genes found here to be associated with cytogenetic resistance have been previously described as being associated with imatinib sensitivity (BTK, PRDX2, PTGS1 and SOCS2). [16] [17] [18] Gene expression profile and cytogenetic response
We have identified 25 genes that are differentially expressed in patients lacking a MCgR at 12 months by using bootstrap Abbreviations: CyR, cytogenetic response; der(5), derivative chromosome 5 detected by conventional cytogenetics; der(9) del (9), deletion on the derivative chromosome 9 detected by FISH; eR, early responders, response at 6 months; NA: not available; NR, non-responder, including minor response (35-99% Ph+) and null response (100% Ph+); R, responder at 12 months, including complete response (1) (0% Ph+) and partial response (1-34% Ph+). Patient 11 was considered as non-responder, owing to the high levels of bcr-abl/abl at 6 and 12 months similar to the case of other non-responders (data not shown).
Genes involved in imatinib resistance R Villuendas et al prediction analysis. These genes are involved in diverse functions, mainly cell adhesion (six genes: COL4A6, DSG1, F8, ITGAE, TNC and VWF) and NF-kB activation (six genes: BIRC4, DEDD, FZD5, FZD7, IKBKB and RIPK3) ( Table 2 and  Supplementary Table 3) .
Twenty-four genes were found to be differentially expressed in early response (6 months). They belong mainly to the functional categories identified as drug metabolism (nine genes: NT5C2, SLC19A2, PTGS1, PRRG1, LRRC2, PRDX2, EIF2A, ALDH1A2 and CDA08), kinases and phosphatases (five genes: Table 2 Genes associated with the cytogenetic response to imatinib. OR12: Odd ratios of the genes associated with the cytogenetic response at 12 months, OR6: Odds ratios of the genes associated with the cytogenetic response at 6 months 
Risk assessment for the cytogenetic response at 12 months
Twelve genes were selected for the multivariate analysis. Those genes, differentially expressed by patients lacking a MCgR at 12 months, had a corrected percentage of prediction of at least 65%, as estimated by univariate bootstrap analysis (Supplementary Table 3 ). A mathematical model was constructed based on factor 1 (as described in Materials and methods), which was able to distinguish between responder and non-responder cases (MCyR at 12 months) (OR/0.25 units in factor 1 ¼ 1.80; 95% confidence interval (CI), 1.21-2.66; P ¼ 0.004) on the basis of the six genes with loads 40.30, as follows:
The model provides a risk value associated with the CgR. With a threshold of 0.5, 19/20 sensitive tumors (95% specificity) and 7/11 resistant tumors (64% sensitivity) were correctly classified, with an 80% overall accuracy of well-classified patients (95% CI, 63-93%), after correcting the over-optimism of the model by bootstrapping (as explained in Materials and methods). In fact, for this predictor, the area under the curve of ordinary receiver operating characteristics (ROC), which may be interpreted as the overall accuracy of the selected model, was 0.82 (Supplementary Figure 1 and Supplementary Materials and methods).
The series was divided into three categories, using the individual patients' predicted risk. Accordingly, there was a low-risk group (probability of failure o33%), an intermediaterisk group (probability of failure between 33 and 66%) and a high-risk group (probability of failure 466%). The real percentages of failure observed in these three groups were 15, 33 and 88%, respectively (Figure 2) .
Validation of the model in an independent sample
The prediction model for the CgR at 12 months, based on six genes, was validated using microarray expression data from a blind set of 12 patients (10 responders/two non-responders) who had been treated with imatinib as a first-line therapy. The same model was applied to predict individual risks of failure ( Figure 2 ). All responders had predicted risk probabilities lower than nonresponders. Regarding the three risk groups mentioned above, all responders were classified in the low-risk group (10 patients), one of the two non-responders was classified in the low-risk group and the other in the intermediate-risk group (Figure 2) .
Discussion
Imatinib has a remarkable activity in CML patients, as demonstrated in multiple trials. 19, 20 However, a significant proportion of patients initially fails, or acquires resistance to this treatment over time. In this study, we decided to use the MCgR at 6 and 12 months as clinical end points. Studies of different groups have demonstrated that patients with poor CgR progress to blast crisis more quickly than those who experience major cytogenetic remissions. A prompt molecular response is also associated with longer progression-free survival. 4, 21 The study has identified an expression profile associated with primary resistance. The classes of genes identified and the lack of mutations in the kinase domain of the bcr-abl gene suggest that this type of resistance is essentially BCR-ABL-independent.
The 46 genes detected that correlation with lack of CgR allows confirmation of, or generates hypotheses concerning, the BTK  DSG1  IL8RB  BCL2L2  PTPN22  SRR  FZD5  ITGAE  PTGS1  BIRC4  SOCS2  COL4A6  F8  IKBKB  DEDD  FZD7  HD  CYP2B6  PPARA  UHF  IGFBP1  IL7R  PRDX2 Genes involved in imatinib resistancebiological mechanism underlying imatinib resistance. A clear relation between imatinib resistance and the expression of genes involved in cell-adhesion inhibition has been observed. Chronic myeloid leukemia is characterized by abnormal trafficking of malignant hematopoietic progenitor cells in the peripheral blood, as a consequence of aberrant adhesive interactions with the bone marrow stroma, 22 caused by kinase-dependent and -independent mechanisms, 23 and linked to cytogenetic resistance to imatinib. 24 The low levels of expression of adhesion molecules detected in imatinib-resistant patients could be related to their inability to respond to imatinib. Although it seems that adhesion defects in CML may be tyrosine-kinase-independent, 25 restoration of celladhesion molecules may be a mechanism of action of imatinib, as has been demonstrated in in vitro studies by Fruehauf et al. 26 for the adhesion molecule L-selectin (CD62L). Likewise, Pelletier et al. 27 have suggested that improvement of adhesion between BCR-ABL-expressing myeloid progenitor cells and bone marrow stroma may be of therapeutic value for human CML.
Tenascin-C (TN-C), a large extracellular matrix (ECM) glycoprotein, is downregulated in the group of non-responders. Tenascin-C functions as an adhesive molecule for bone marrow cells, and inhibits cell migration. It is located in the 9q33 region, 15 Mb from the abl1 locus. Large deletions in the derivative chromosome 9, consisting of many megabases, have been associated with poor prognosis, resistance to IFN 28 and to imatinib, 29 although the treatment with imatinib has been described as overcoming the adverse prognostic significance of der(9) deletions. 30 In our series of cases, CgRs were uniformly lower in patients with der(9) deletions.
Overexpression of IKBKB in our imatinib-resistant CML patients suggests that NF-kB activation may play an important role in this process. IKBKB phosphorylates NF-kB inhibitors, leading to the dissociation of the inhibitor/NF-B complex, degradation of the inhibitor and activation of NF-kB, whose antiapoptotic function in tumors has been linked to the acquisition of resistance to chemotherapy. 31, 32 Indeed, NF-kB activation has been found in CML cells resistant to imatinib mesylate, 33 and it is interesting to note that bortezomib, a proteasome inhibitor, downregulates NF-kB activity and induces apoptosis in bcr-abl-positive cell lines. 12, 33 Furthermore, other genes associated with NF-kB activation, such as BIRC4/ XIAP, inhibitor of apoptosis protein (IAP) and the antiapoptotic c-FLIP genes (CFLAR), are also found to be associated with resistance to imatinib in this series of CML cases. C-FLIP, whose increased expression correlates in our series with lack of CgR at 6 months, is an apoptosis-regulator protein, which may function as a crucial link between cell-survival and cell-death pathways in mammalian cells. Birc4/XIAP is an apoptosis suppressor that inhibits caspase-3, -7 and -9. XIAP may be responsible for resistance to apoptosis induced by cytotoxic drugs. Recent studies suggest that XIAP is a key molecule in apoptosis resistance in human cancer, and a potential therapeutic target. 34 The involvement of molecules with PTPase or kinase activity is also detected in this study, where PTPN22 and BTK are overexpressed in non-responder patients. PTPN22 or LYP was identified as a lymphocyte-specific PTPase, 35 although a potential function of LYP in myeloid cell development has been suggested, 36 and an antagonist role of LYP regulating the expression of bcr-abl has been described. 36 Overexpression of PTPs has been shown to cause persistent activation of the PTK with concomitant cell transformation, suggesting a causal role for this PTP in tumorigenesis. 37 A set of genes that this study showed to be associated with early imatinib resistance regulates drug metabolism. The gene CYP2B6 encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases, which catalyze many reactions involved in drug metabolism. CYP2B6 is known to metabolize some xenobiotics, such as the anticancer drug cyclophosphamide, although it has not previously been implicated in imatinib metabolism. 38 Also associated with drug metabolism is PTGS1 (cyclooxygenase (COX)1). This finding confirms previous observations in cell lines. 16 The COX1 gene is involved in membrane transport and drug metabolism and resistance. It plays an important role in regulating or promoting cell proliferation in some normal and neoplastic transformed cells. 39 This enzyme is inhibited by non-steroidal anti-inflammatory drugs. 39 Some of the genes found here to be associated with CgR have been previously described as being associated with variations in imatinib sensitivity, such as BTK, PRDX2 and COX1. 16, 17 Augmentation of SOCS2 expression has also been described as being associated with refractoriness to imatinib or relapse after initial response. 18 Although some genes have been previously described with microarray technology, an important group of these has not. 24, 40, 41 These differences could be owing to the use of different array platforms or different statistical analyses, as well as the number of patients. A larger set of patients is probably required to arrive at a definitive conclusion.
The identification of genes whose expression is associated with an increased probability of failure could be helpful for selecting more appropriate imatinib doses or drug combinations. The molecular signature of imatinib resistance has allowed us to identify a group of six genes (BIRC4, FZD7, IKBKB, IL-7R, TNC, VWF), whose expression correlates closely with imatinib cytogenetic-resistance (80%). Given that this study was carried out in patients who were refractory to IFN-a, we were interested to determine whether this finding could be applied to a group of naïve, previously untreated patients. In fact, 83% of the patients in this smaller validation group were properly classified.
In conclusion, our study identified a set of genes potentially involved in resistance to imatinib, and yielded a prediction model based on six genes, which may be further explored in clinical and experimental models as potential clinical predictors or therapeutic targets. Our results suggest that largely BCR-ABLindependent mechanisms are potentially related to primary imatinib resistance in CML patients. 11, 17 
